Web28 aug. 2012 · Background Mycophenolate mofetil is an immunosuppressive agent approved for the prophylaxis of renal, cardiac and hepatic transplant rejection. With its proven immunosuppressive effects and favourable toxicity profile, mycophenolate mofetil was postulated as a potential candidate for treating rheumatoid arthritis. Objective To … Web30 aug. 2024 · Objective. This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials.
Systematic review and meta-analysis of randomised trials and …
Web1 mrt. 2024 · Arthritis Rheum. (2004) 51:278–83. doi: 10.1002/art.20240. PubMed Abstract CrossRef ... 19. Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody ... Web6 jul. 2010 · Mycophenolate mofetil is classified as a similar drug to methotrexate - it seems to have an effect on the immune system. It's not as commonly used as drugs … does it matter where you go to law school
mycofenolaatmofetil - Farmacotherapeutisch Kompas
Web4 apr. 2024 · ObjectiveThis study aimed to compare the efficacy and safety (infection events) between rituximab (RTX), tacrolimus (TAC), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) as induction therapies in lupus nephritis (LN).MethodsElectronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched from … Web18 dec. 2012 · Arthritis Rheum. 2012, 64: 285-296. 10.1002/art.30645. Article PubMed Central CAS PubMed Google Scholar Kiani AN, Magder LS, Petri M: Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int. 2012, 32: 2701-2705. 10.1007/s00296-011-2048-y. Web19 jan. 2024 · Mycophenolate mofetil (MMF) inhibits B- as well as T-cell function and is often used for intensified immunosuppression (e.g., after rejection) . Interestingly, MMF therapy appears to reduce the response to hepatitis B immunization in children with rheumatoid arthritis [ 39 ]. fabrice lorthiois